These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 22723322

  • 1. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M.
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [Abstract] [Full Text] [Related]

  • 2. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T.
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [Abstract] [Full Text] [Related]

  • 3. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators.
    JAMA; 2016 Aug 16; 316(7):722-33. PubMed ID: 27533157
    [Abstract] [Full Text] [Related]

  • 4. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide.
    Tanaka S, Kuroda T, Sugimoto T, Nakamura T, Shiraki M.
    Curr Med Res Opin; 2014 May 16; 30(5):931-6. PubMed ID: 24392946
    [Abstract] [Full Text] [Related]

  • 5. 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk.
    Sugimoto T, Shiraki M, Fukunaga M, Hagino H, Sone T, Nakano T, Kishimoto H, Ito M, Yoshikawa H, Kishida M, Irie C, Nakamura T.
    Adv Ther; 2017 Jul 16; 34(7):1727-1740. PubMed ID: 28631217
    [Abstract] [Full Text] [Related]

  • 6. Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis.
    Fujita T, Fukunaga M, Itabashi A, Tsutani K, Nakamura T.
    Calcif Tissue Int; 2014 Feb 16; 94(2):170-5. PubMed ID: 23963633
    [Abstract] [Full Text] [Related]

  • 7. Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study.
    Sugimoto T, Shiraki M, Fukunaga M, Kishimoto H, Hagino H, Sone T, Nakano T, Ito M, Yoshikawa H, Minamida T, Tsuruya Y, Nakamura T.
    Osteoporos Int; 2019 Nov 16; 30(11):2321-2331. PubMed ID: 31392401
    [Abstract] [Full Text] [Related]

  • 8. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
    Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S.
    Osteoporos Int; 2021 Nov 16; 32(11):2301-2311. PubMed ID: 34002252
    [Abstract] [Full Text] [Related]

  • 9. [Once-weekly teriparatide treatment on osteoporosis].
    Nakano T.
    Clin Calcium; 2014 Jan 16; 24(1):100-5. PubMed ID: 24369286
    [Abstract] [Full Text] [Related]

  • 10. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.
    N Engl J Med; 2001 May 10; 344(19):1434-41. PubMed ID: 11346808
    [Abstract] [Full Text] [Related]

  • 11. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.
    Lancet; 2018 Jan 20; 391(10117):230-240. PubMed ID: 29129436
    [Abstract] [Full Text] [Related]

  • 12. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML, Chen P, Glass EV, Kallmes DF, Delmas PD, Mitlak BH.
    J Bone Joint Surg Am; 2009 Jun 20; 91(6):1329-38. PubMed ID: 19487509
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.
    J Bone Miner Res; 2006 Nov 20; 21(11):1785-90. PubMed ID: 17002571
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
    Harvey NC, Kanis JA, Odén A, Nakamura T, Shiraki M, Sugimoto T, Kuroda T, Johansson H, McCloskey EV.
    Osteoporos Int; 2015 Sep 20; 26(9):2347-53. PubMed ID: 26092062
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
    Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, Sone T, Taguchi A, Tanaka S, Ohashi M, Ota Y, Shiraki M.
    Osteoporos Int; 2017 Jan 20; 28(1):389-398. PubMed ID: 27631091
    [Abstract] [Full Text] [Related]

  • 19. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.
    Mori S, Hagino H, Sugimoto T, Tanaka S, Mitomo Y, Takahashi K, Sone T, Nakamura T, Soen S.
    Osteoporos Int; 2023 Jan 20; 34(1):189-199. PubMed ID: 36239756
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.